Use of Antifungal Combination Therapy: Agents, Order, and Timing
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Given the substantial morbidity and mortality related to invasive fungal infections, treatment with a combination of antifungal agents is often considered. A growing body of literature from in vitro studies, animal models, and clinical experience provides data evaluating this approach. This review describes combination antifungal strategies for the management of cryptococcal meningitis, invasive candidiasis, invasive aspergillosis, and rare mold infections. The potential effects that sequencing and timing have on the efficacy of such approaches are discussed, with a focus on recent clinical data in this arena.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“Therefore, the routine use of combination therapy for candidemia is not recommended [ 62 ].”
BackgroundPerfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationCombination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.917-921.2006 · Cited by 298
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213 · cited 2×
“These agents, which include caspofungin, micafungin, and anidulafungin, destabilize the fungal cell wall by depleting glucans, which are necessary to maintain its stability [8, 41].”
Background
Cited by
Candida albicans—The Virulence Factors and Clinical Manifestations of Infection
Talapko, J., Juzbašić, M., Matijević, T., Pustijanac, E., Bekić, S., Kotris, I., & Škrlec, I. (2021) · Journal of Fungi · doi:10.3390/jof7020079 · Cited by 794
“albicans for antifungal drugs, the patient’s sensitivity to the antifungal agent, and the severity of the disease, relevant comorbidities, and brain involvement, heart valves, or internal organs [174,175].”
BackgroundEchinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“The clinical evidence in support (or not) of combination therapy employing various antifungal agents for different IFIs has been recently reviewed,([177]) yet there are no RCTs examining the efficacy of combination antifungal therapy.”
BackgroundAzole antifungals: 35 years of invasive fungal infection management
Allen, D., Wilson, D., Drew, R., & Perfect, J. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1032939 · Cited by 255
“With the exception of cryptococcal meningitis, data supporting the routine use of these various combination therapies for invasive fungal diseases are mostly limited to in vitro studies, animal models, observational studies and anecdotal case reports [62].”
BackgroundSelf-citationCross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi
Delma, F. Z., Al-Hatmi, A. M. S., Brüggemann, R. J. M., Melchers, W. J. G., de Hoog, S., Verweij, P. E., & Buil, J. B. (2021) · Journal of Fungi · doi:10.3390/jof7110909 · Cited by 96
“In a cohort of patients treated for cryptococcal meningitis, CSF 5-FC concentrations were 84% of the corresponding plasma concentrations [16].”
Background
Metadata
- Authors
- Johnson, M. D., & Perfect, J. R.
- Venue
- Current Fungal Infection Reports
- Published
- 2010-05-01
- Volume
- 4
- Issue
- 2
- Pages
- 87-95
- ISSN
- 1936-3761 (ISSN-L)
- 1936-377X
- OpenAlex
- W2015237258
- Cited by
- 104
- References
- 7
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Antifungal Combination Therapy: Agents, Order, and Timing. https://app.cochat.ai/papers/10.1007/s12281-010-0018-6
- The paper
- Johnson, M. D., & Perfect, J. R. (2010). Use of Antifungal Combination Therapy: Agents, Order, and Timing. Current Fungal Infection Reports. https://doi.org/10.1007/s12281-010-0018-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.